Mundipharma Korea is drastically reorganizing its opioid analgesics specialty drug business unit. This is the second time the Korean branch made such large-scale reshuffles since the bankruptcy of its US headquarters, Purdue Pharma in August 2022. The company is known to be searching for a domestic pharmaceutical company to take over the sales of its opioid analgesics and manage its sales with a minimum number of employees.

According to industry sources on the 5th, the company is conducting an Early Retirement Program (ERP). This time the target is 25 sales and marketing employees in the specialty drug business unit for the opioid analgesics.

The ERP compensation terms are monthly base